Dear Editor, We carefully read the meta-analysis by Malekahmadi et al. recently accepted for publication in Pharmacological Research with a little criticism [1]. Our concerns regard the fact that not every included study meets the inclusion criteria of the meta-analysis. As a matter of fact, the authors considered 9 non-randomized clinical studies (non-RCTs) (references 26, 28, 33, 34, 36, 38, 41, 44, 45 in the paper), and a clinical trial (reference 24 in the paper) testing the effect of Oligopin® supplementation, which is characterized by a higher content in low molecular weight oligomeric procyanidins than Pycnogenol® (∼20 % vs. 5 %).
Fogacci F, T.G. (2020). Are we really sure about the pycnogenol antihypertensive effect?. PHARMACOLOGICAL RESEARCH, 151, 1-1 [10.1016/j.phrs.2019.104543].
Are we really sure about the pycnogenol antihypertensive effect?
Cicero AFG.
2020
Abstract
Dear Editor, We carefully read the meta-analysis by Malekahmadi et al. recently accepted for publication in Pharmacological Research with a little criticism [1]. Our concerns regard the fact that not every included study meets the inclusion criteria of the meta-analysis. As a matter of fact, the authors considered 9 non-randomized clinical studies (non-RCTs) (references 26, 28, 33, 34, 36, 38, 41, 44, 45 in the paper), and a clinical trial (reference 24 in the paper) testing the effect of Oligopin® supplementation, which is characterized by a higher content in low molecular weight oligomeric procyanidins than Pycnogenol® (∼20 % vs. 5 %).I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
